

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
RESPONSE UNDER RULE 116
EXPEDITED HANDLING PROCEDURES

Atty Dkt. 2801-18
C#/M#
Group Art Unit: 1644
Examiner: Jamroz

Date: November 20, 2002

Corres. and Mail #18
BOX AF 9ND

In re Patent Application of

BOTTAZZI et al.

Serial No. 09/555,473

Filed: February 26, 2002

Title: PHARMACEUTICAL COMPOSITIONS CONTAINING THE LONG
PENTRAXIN PTX3

Assistant Commissioner for Patents
Washington, DC 20231



RECEIVED

NOV 25 2002

TECH CENTER 1600/2900

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
Previously paid for	20	(at least 20) =	0 x \$ 18.00	\$ 0.00
Independent claims after amendment	0	minus highest number		
Previously paid for	3	(at least 3) =	0 x \$ 84.00	\$ 0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)				\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this Paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)				\$ 920.00
Terminal disclaimer enclosed, add \$ 110.00				\$ 0.00
<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)				\$ 0.00
<input type="checkbox"/> Please enter the previously unentered, filed				
<input type="checkbox"/> Submission attached				

SUBTOTAL \$ 920.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00
☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Other: Amendment After Final Rejection; Copy of Toxicity of polyacrylamide and acrylamide monomer; 0.00
Copy of Experimental study on the toxic effects of hydrophilic polyacrylamide gel; Submission of Formal
Drawings (2 Sheets); Three-Month Extension Petition Fee; Notice of Appeal; Notice of Appeal Fee

TOTAL FEE ENCLOSED \$ 920.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:plb

NIXON & VANDERHYE P.C.
By Atty.: B. J. Sadoff, Reg. No. 36,663

Signature: 

11/21/2002 TBESHAH1 00000071 09555473

02 FC:1253

920.00 0P



#20/D
gnd
11/20/02
A/E

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BOTTAZZI et al.

Atty. Ref.: 2801-18

RECEIVED

NOV 25 2002

Serial No. 09/555,473

Group: 1644

TECH CENTER 1600/2900

Filed: February 26, 2002

Examiner: Jamroz

For: PHARMACEUTICAL COMPOSITIONS CONTAINING THE LONG PENTRAXIN
PTX3

* * * * *

November 20, 2002

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT UNDER RULE 116

Responsive to the Official Action dated May 20, 2002, entry and consideration of the following amendments and remarks are requested; the period for response having been extended up to and including January 20, 2003 by submission of the requisite extension petition, extension fee, Notice of Appeal and Notice of Appeal fee, attached.

IN THE CLAIMS

Amend the claims as follows.

Cancel claims [✓]1-8 and [✓]12-16[✓], without prejudice.

Add the following claims.

--17. (New) An orally, parenterally, transdermally or subcutaneously

administrable pharmaceutical composition containing as an active ingredient the amino acid sequence of the long pentraxin PTX3 having sequence SEQ ID NO: 1, and a pharmaceutically acceptable excipient.

D1